Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | RECQL | P46063 | 2/20 | 0.79 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.79 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | F3 | P13726 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL1367016 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL2128854 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL1827856 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL7629150 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL2128849 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL2832028 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL18788602 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL28370740 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL29371090 | 1.00 | CYP1A2 (0.79) | CYP1A2CYP2C9MAPTPLIN1LMNA | |
| Chloroform SCHEMBL1043119 | 0.98 | CYP1A2 (0.83) | CYP1A2CYP2C9MAPTPLIN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 838 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040462-A | Spiropyrazinone compound, preparation method and application | 北京工业大学 | 2025-05-27 | — | — | CN | claimed |
| CN-120040461-A | Spirobarbitudes compound, preparation method and application | 北京工业大学 | 2025-05-27 | — | — | CN | claimed |
| CN-119569557-A | Method for synthesizing linear carboxylic acid by olefin hydrocarboxylation with formic acid as carbonyl source | 常州大学 | 2025-03-07 | — | — | CN | claimed |
| CN-118406075-A | Silicon-containing polycyclic chromone skeleton compound, preparation method and application thereof | 遵义医科大学 | 2024-07-30 | — | — | CN | claimed |
| CN-118344383-A | 11-Membered ring compound containing Z-type double bond and preparation method thereof | 天津大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118344303-A | Benzo [ c ] [1,5] oxazacine compound and synthesis method thereof | 江苏师范大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118324794-A | Nitrogen-containing silicon cyclohexene compound and preparation method thereof | 扬州大学 | 2024-07-12 | — | — | CN | claimed |
| CN-118307475-A | Preparation method of stable isotope labeled fluxapyroxad internal standard reagent | 谱同生物医药科技(常州)有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-118307554-A | E-containing double bond 11-membered ring compound and preparation method thereof | 天津大学 | 2024-07-09 | — | — | CN | claimed |
| CN-118290432-A | Trans-cycloolefin compound and preparation method and application thereof | 华中师范大学 | 2024-07-05 | — | — | CN | claimed |
| CN-108440526-A | A kind of chirality barbital spiral shell Tetrahydroquinolinesas and preparation method | 北京工业大学 | 2018-08-24 | — | — | CN | claimed |
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | claimed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| EP-1648858-B1 | METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2008-07-02 | — | — | EP | claimed |
| US-20060281949-A1 | Method for production $g(a),$g(b)-unsaturated amide compounds | SIEGFRIED GENERICS INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | claimed |
| EP-1068209-B1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | NOVARTIS INT PHARM LTD (BM) | 2005-09-14 | — | — | EP | claimed |
| US-20050049278-A1 | Benzo[1,3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same | ATHERSYS, INC. | 2005-03-03 | — | — | US | claimed |
| US-20030130512-A1 | Process for the production of purine derivatives and intermediates therefor | DPT LABORATORIES, LTD. | 2003-07-10 | — | — | US | claimed |
| US-6555685-B1 | Preparing purine derivatives, such as famiciclovir and penciclovir, by reacting, in the presence of a palladium catalyst and ligand; by-product inhibition; efficiency | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| EP-0444889-A1 | Novel synthesis of carbapenem intermediates | MERCK & CO. INC. (US) | 1991-09-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130512-A1 | Process for the production of purine derivatives and intermediates therefor | TYMP, DPYD, PNP | CYP1A2 1949/4885CYP2C9 763/4885MAPT 3521/4885 |
| US-20060281949-A1 | Method for production $g(a),$g(b)-unsaturated amide compounds | GSTA2, GSTO1, GLB1 | CYP1A2 288/4885CYP2C9 491/4885MAPT 3147/4885 |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | CYP1A2 155/4885CYP2C9 479/4885MAPT 4717/4885 |
| US-20050049278-A1 | Benzo[1,3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same | CYP4X1, BBOX1, CYP1B1 | CYP1A2 30/4885CYP2C9 16/4885MAPT 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.